Table 4.

Summary of the main results of antioxidant therapy in patients with Chagas cardiomyopathy

Study	Study design	Intervention	Outcome
Barbosa et al. (2016)	Prospective, open cohort	Benznidazole (5 mg kg day−1, minimum dose 300 mg daily) for 2 months followed by Vitamin C (500 mg day−1) and E (800 UI day-1) supplementation for 6 months.	Reduction of PVC episodes in patients with severe chagasic cardiopathy; Reduction of serum markers of oxidative stress; In patients with a lower degree of cardiac damage, the reduction in PVC prevalence was not significant.
Budni et al. (2013)	Prospective, open cohort	Carvedilol (12.5 mg, in a total daily dose of 37.5 mg) for 6 months; 6 months washout period, following combination of carvedilol with vitamins E (800 IU) and C (500 mg) in a single daily dose for 6 months.	Reduced levels of oxidative stress, as evidenced by decreased markers (SOD, TARBS, NO, GPx, GR CAT, ADA), PC, was most pronounced when carvedilol was associated with antioxidant vitamins.
Ribeiro et al. (2010)	Prospective, cohort	Benznidazole (5 mg kg day-1) for 2 months following Vitamin C (500 mg day-1) and E (800 UI day-1) supplementation for 6 months.	After treatment with BNZ: SOD, CAT, GPx and PC activities were increased and vitamin E level reduced; After supplementation: Reduction of SOD, GPx and GR activities; Reduced levels of PC, TBARS, NO and GSH.
Maçao et al. (2007)	Prospective cohort	Supplementation with Vitamin C (500 mg day-1) and E (800 UI day-1) for 6 months.	Reduced plasma levels of TBARS, PC and increased GSH content of erythrocytes in group I; Less plasma vitamin E when the disease is more severe; Reduction MPO and GST in groups II, III and IV; Increased GR activity and GPx in group I; Increased catalase activity (CAT) in Group II; Increase of NO in groups II and III.